Skip to main content

Table 3 Simultaneous multivariate Cox regression analysis for PFS in the upfront ABI group

From: Impact of pretreatment anemia on upfront abiraterone acetate therapy for metastatic hormone-sensitive prostate cancer: a multicenter retrospective study

Variable

Factor

P value

Hazard ratio

95% CI

Age ≥75 years

Presence

0.280

0.51

0.15-1.73

ECOG-PS ≥1

Presence

0.750

1.15

0.35-3.81

Initial PSA ≥100 ng/ml

Presence

0.810

0.92

0.14-5.96

Gleason score ≥9

Presence

0.910

0.94

0.31-2.82

Visceral metastasis

Presence

0.760

0.67

0.13-3.46

EOD

0-4

0.380

0.74

0.38-1.44

ALP ≥322 IU/L

Presence

0.940

0.94

0.19-4.59

LDH ≥222 IU/L

Presence

0.055

3.51

0.97-12.3

Anemia

Presence

0.016

5.64

1.39-20.9

  1. PFS progression-free survival, ABI abiraterone acetate, CI confidence interval, ECOG-PS Eastern Cooperative Oncology Group performance status, PSA prostate specific antigen, EOD extent of disease, ALP alkaline phosphatase, LDH lactate dehydrogenase